Christopher Raymond

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...

The market’s skepticism around Aptinyx Inc’s (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initiated coverage of Aptinyx with an Overweight rating and a price target of $10. The...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced positive preliminary Phase 1/2/3 results Tuesday for a study that evaluated its antibody cocktail REGN-COV2 in non-hospitalized coronavirus patients.  REGN-COV2 is composed of two anti-spike monoclonal antibodies that target...

Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Tuesday interim Phase 1 readout for INO-4800, its DNA vaccine candidate against the novel coronavirus. The Inovio Analyst: Piper Sandler analyst Christopher Raymond maintained a Neutral rating and $8 price target for Inovio. The Inovio Thesis:...

Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) is not an outright buy at this point in time, according to an analyst at Piper Sandler. The Inovio Analyst Christopher Raymond maintained a Neutral rating on Inovio shares with an $8 price target.  The Inovio Thesis The 12...